Compare Davita Inc (DVA) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Petróleo Brasileiro SA — how do they compare? Davita Inc trades at $178.35 (market cap $11.38B), while Petróleo Brasileiro SA trades at $17.8 (market cap $112.19B). The key difference: Petróleo Brasileiro SA is far larger — about 9.9× Davita Inc's market cap, and Petróleo Brasileiro SA pays a 9.42% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | PBR | |
|---|---|---|
Market Cap | $11.38B | $112.19B |
Sector | Health | Technology |
52-Week High | $240.96 | $22.03 |
52-Week Low | $103.87 | $11.54 |
Enterprise Value | $24.10B | $172.61B |
Dividend Yield | — | 9.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $181.72, down 1.07% on the day, with technical indicators showing a mixed but overall bullish signal. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.02 surpassing estimates. Revenue growth is steady, reaching $13.64B in 2025, though net income margin has fluctuated. Analyst sentiment is cautiously optimistic with a consensus price target of $232.25, representing significant upside potential from current levels.
The outlook for DVA is positive, driven by strong volume growth and strategic execution, but faces risks from reimbursement pressures and a high debt load. Investment opportunity lies in the valuation discount to analyst targets and consistent earnings beats, while key risks include payer mix challenges and macroeconomic factors affecting healthcare spending.
Petrobras (PBR) trades at $17.76, down 3.11% today, amid bearish technical signals despite strong Q2 2026 results showing record production and earnings growth. The company maintains robust fundamentals with a P/E of 4.53, ROE of 30.77%, and consistent dividend payments, though cash flow turned negative in 2026. Recent news highlights production exceeding forecasts and strategic expansions in deepwater operations.
PBR presents a value opportunity with attractive valuations and high profitability, but faces headwinds from regulatory uncertainty and volatile oil prices. Analyst consensus is bullish (50% Buy ratings), yet technical indicators suggest near-term pressure. Investors should weigh strong fundamentals against geopolitical and operational risks in the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
